Articles
Delivery logistics is critical to COVID-19 vaccine availability
The opening months of 2021 have revealed the logistical and political intricacies of COVID-19 vaccine manufacturing and deployment. The unprecedented requirement of vaccinating the world against a single virus has demonstrated the power of modern medicine and logistics capabilities.
The...
Clinical Trials
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of the company’s...
Drug Research
Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands
Sanofi has entered into an agreement with Janssen Pharmaceutical NV and Janssen Pharmaceuticals, Inc., two of the Janssen Pharmaceutical Companies of Johnson & Johnson, under which Sanofi will support manufacturing of Janssen´s COVID-19 vaccine in order to address the...
News
Vetter continues its successful performance at the 2021 CMO Leadership Awards
Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), was granted the 2021 CMO Leadership Awards in five core categories – quality, expertise, compatibility, capabilities, and service. The award, now in its tenth year, was given by the...
News
Peli BioThermal Launches new Webinar Series
Peli BioThermal, the global name in temperature controlled packaging, partners with industry experts to offer InnovationShare, a new webinar series focusing on best practices in clinical and commercial supply chain management. InnovationShare debuts in early March with monthly courses...
Clinical Trials
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the...
News
COVID-19 Vaccine AstraZeneca authorised for use in the EU
AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the EU for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.
Following review of the application, the Committee for Medicinal...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read